• Mutation; HGNC; HGNC:6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
  

DOI=10.5282/edoc.26548
Martina Messner;
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=32652772; DOI=10.1096/fj.202001128R
Martina Messner, Sabine Schmitt, Maximilian Alexander Ardelt, Thomas Frohlich, Martin Muller, Helmut Pein, Petra Huber-Cantonati, Carina Ortler, Lars M. Koenig, Lena Zobel, Andreas Koeberle ...Show all 18 authors... , Georg J. Arnold, Simon Rothenfusser, Alexandra K. Kiemer, Alexander L. Gerbes, Hans Zischka, Angelika M. Vollmar, Johanna Pachmayr; Show fewer authors
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020)